Epigenetics

Epigenetics is the control of gene expression without altering the DNA sequence, including DNA methylation, genomic imprinting, maternal effects, gene silencing, nucleolus dominant, dormant transposon activation, and RNA editing. In contrast to classical genetics, which focuses on the effects of gene sequences on biological functions, epigenetics focuses on the mechanisms by which these "epigenetic phenomena" are established and maintained.

Cat. No.	Product name
BP13917	Hispidulin
BP13917	Hispidulin, a natural flavone with a broad spectrum of biological activities, is a Pim-1 inhibitor (IC50: 2.71 μM).
BP13916	Hispidin
BP13916	Hispidin is a polyphenol originally, including antioxidant, anti-inflammatory, and cytoprotective properties
BP13915	Hexamethylene bisacetamide
BP13915	Hexamethylene bisacetamide inhibits BET Bromodomain Proteins.
BP13914	1-HEXACOSANOL
BP13914	Hexacosanol activates AMPK and hepatic autophagy and inhibits SREBP2, resulting in hypocholesterolemic activities and improvement of hepatic steatosis.
BP13913	HDACs/mTOR Inhibitor 1
BP13913	HDACs/mTOR Inhibitor 1 is a dual HDACs and mammalian target of Rapamycin (mTOR) target inhibitor for treating hematologic malignancies (IC50s: 0.19 nM, 1.8 nM, 1.2 nM, and >500 nM for HDAC1, HDAC6, mTOR and PI3Kα).
BP13912	HDAC-IN-7
BP13912	HDAC-IN-7 (Chidamide impurity) is an impurity of Chidamide. Chidamide is a potent and orally bioavailable inhibitor of HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10).
BP13911	HDAC-IN-5
BP13911	HDAC-IN-5 is a histone deacetylase (HDAC) inhibitor.
BP13910	HDAC-IN-4
BP13910	HDAC-IN-4 is a selective HDAC6 and HDAC10 inhibitor (pIC50s: 7.2 and 6.8 in BRET assay) with antitumoral activity.
BP13909	HDAC-IN-3
BP13909	HDAC-IN-3 is a potent histone deacetylase (HDAC) inhibitor, and treatment chronic inflammatory disorders.
BP13908	HA-1004 dihydrochloride
BP13908	HA-1004 dihydrochloride is an inhibitor of PKA, PKC, cGKI, MYLK, and calcium channel protein
BP13907	HA-100
BP13907	HA-100 is an inhibitor of protein kinase
BP13906	Guadecitabine sodium
BP13906	Guadecitabine sodium is a inhibitor of second-generation DNA methyltransferases (DNMT).
BP13905	GSK-LSD1 dihydrochloride
BP13905	GSK-LSD1 2HCl is a specificity irreversible LSD1 inhibitor (IC50: 16 nM). The selectivity of GSK-LSD1 for LSD1 is >1000 fold over other closely related FAD utilizing enzymes (i.e. MAO-A, LSD2, MAO-B).
BP13904	GSK-J4 Hydrochloride
BP13904	GSK-J4 is a cell permeable, potent and selective histone demethylase(JMJD3 )inhibitor. is an ethyl ester derivative of the GSK-J1 with an IC50 value greater than 50 μM in vitro.
BP13903	GSK-J1 lithium salt
BP13903	GSK-J1 lithium salt is a potent inhibitor of me2-demethylases JMJD3/H3K27me3/KDM6B and UTX/KDM6A (IC50: 60 nM towards KDM6B).
BP13902	GSK-J1
BP13902	GSK-J1 is a highly potent H3K27 histone demethylase inhibitor with IC50 of 28 nM and 53 nM in cell-free assays for JMJD3 (KDM6B) and UTX (KDM6A), respectively, >10-fold selectivity over other tested demethylases.
BP13901	GSK9311
BP13901	GSK9311 inhibits BRPF bromodomain (pIC50: 6.0 and 4.3 for BRPF1 and BRPF2, respectively). GSK9311 is a less active analog of GSK6853. It can be used as a negative control.
BP13900	GSK9311 hydrochloride
BP13900	GSK9311 hydrochloride, a less active analog of GSK6853, can be used as a negative control. GSK9311 hydrochloride inhibits BRPF bromodomain (pIC50s: 6.0 and 4.3 for BRPF1 and BRPF2).
BP13899	GSK8814
BP13899	GSK8814 is a selective and ATAD2/2B bromodomain chemical probe and inhibitor (binding constant pKd=8.1 and a pKi=8.9 in BROMOscan). GSK8814 displays 500-fold selectivity for ATAD2 over BRD4 BD1. GSK8814 binds to ATAD2 and BRD4 BD1 (pIC50s: 7.3 and 4.6).
BP13898	GSK8573
BP13898	GSK8573 is an inactive control compound for GSK2801. GSK8573 has binding activity to BRD9 (Kd of 1.04 μM).